Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1002388/000100238813000006/accl-201212311210xk.htm
April 2014
February 2014
January 2014
December 2013
December 2013
October 2013
September 2013
July 2013
July 2013
June 2013
• | Completed three acquisitions that add important domain expertise and technology capabilities that further our strategy to optimize the innovation lifecycle from research through commercialization. |
◦ | HEOS, a secure Cloud-based information management workspace for scientific collaboration, accelerates and streamlines collaborative drug-discovery. |
◦ | Aegis Analytical Corporation (Aegis), the leading provider of process management informatics software, further expands the footprint in downstream operation with solutions that help aggregate, contextualize and analyze manufacturing, quality and product development data. |
◦ | Vialis AG, a leading systems integrator with deep experience implementing and supporting paperless laboratory solutions, further strengthening Accelrys' position in the laboratory informatics software market. |
• | Delivered new product releases in the core product lines and significantly progressed the integration roadmap for the solutions acquired into the portfolio, including: |
◦ | New Accelrys Enterprise Platform (AEP), the industry's first scientifically aware, service-oriented architecture (SOA) that enables integration and deployment of broad scientific solutions (Platform) |
◦ | New biology capabilities from screening through pre-clinical development in the Accelrys Electronic Laboratory Notebook (Enterprise Lab Management) |
◦ | New Process Management and Compliance suite, a unified approach to product development and process management which combines the capabilities of the Accelrys ELN, Accelrys Lab Execution System (LES), Accelrys Electronic Batch Records (EBR) and the Accelrys Enterprise Platform (Enterprise Lab Management) |
◦ | New integration between Accelrys Materials Studio and AEP, enabling computational scientists to collaborate across the enterprise; deepened biotherapeutics capabilities in Accelrys Discovery Studio (Modeling and Simulation) |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1002388/000100238813000006/accl-201212311210xk.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Accelrys, Inc..
Accelrys, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Accelrys, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ACCL
CIK: 1002388
Form Type: 10-K Annual Report
Accession Number: 0001002388-13-000006
Submitted to the SEC: Wed Mar 06 2013 5:35:06 PM EST
Accepted by the SEC: Thu Mar 07 2013
Period: Monday, December 31, 2012
Industry: Prepackaged Software